Our findings of a marked difference in survival between individuals whose colon tumors have high versus low CEMIP in our patient cohort will clearly merit testing in follow-up studies of larger cohorts of stage III and of stage II plus III colon cancer cases, as well as in cohorts of sufficient size to detect possible effects of CEMIP expression on outcome of stage II only colon cancer cases. This evidence concerns the gene CEMIP and colonic neoplasm.